Aprea Therapeutics, Inc. Common stock
APREAprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company specializes in deploying its proprietary DNA damage response (DDR) pathway inhibitors to treat various malignancies, aiming to improve outcomes for patients with difficult-to-treat cancers.
Company News
Aprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in...
Aprea Therapeutics reported progress in its clinical trials for ATRN-119 and APR-1051, with early evidence of anti-tumor activity and continued enrollment. The company has sufficient cash runway into early Q2 2026.
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential
